BioCentury

1. Back to School

Building sustainable biotechs

2. Case study

Argenx

3. Case study

Genmab

4. Case study

Regeneron

5. Case study

Vertex

6. Up-and-comers

17 Growth Companies

7. Expanding universe

Public biotechs

8. M&A Sweet Spot

By market cap

ARTICLE | Finance

Tier-jumpers: Building the road to sustainable biotechs. Back to School 2023

How companies can build value and climb market cap tiers to reach the top

By C. Simone Fishburn, Editor in Chief, Stephen Hansen, Director of Biopharma Intelligence, and Lauren Martz, Executive Director of Biopharma Intelligence
September 1, 2023 3:18 PM UTC

The market reset has been a healthy thing for biotech, according to almost everyone. Call it greed, call it investor FOMO, call it exuberance, call it divorce from reality, call it what you will, but the number of biotechs created in the past half-decade, and in many cases their valuations, were not underpinned by realistic potential for value creation.

So while companies living on fumes may not be pleased about it, there’s broad hope that this market-driven winnowing will leave the biotech ecosystem with a better crop of companies from which to build. ...